Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Bibliographic Details
Main Authors:	Atkins, Michael B, Gupta, Shilpa, Choueiri, Toni K, McDermott, David F, Puzanov, Igor, Tarazi, Jamal, Keefe, Stephen, Rosbrook, Brad, Chakrabarti, Debasis, Plimack, Elizabeth R
Format:	Online
Language:	English
Published:	BioMed Central 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649476/

Similar Items

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
by: Rini, Brian I., et al.
Published: (2014)

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours
by: Hoh, C K, et al.
Published: (2014)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
by: Cella, D, et al.
Published: (2013)

Pembrolizumab
by: Khoja, Leila, et al.
Published: (2015)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
by: Martin, L P, et al.
Published: (2012)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
by: Escudier, B, et al.
Published: (2014)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
by: Ribrag, Vincent, et al.
Published: (2015)

Pembrolizumab-associated sarcoidosis
by: Cotliar, Jonathan, et al.
Published: (2016)

Into the Clinic With Nivolumab and Pembrolizumab
by: Shu, Catherine A., et al.
Published: (2016)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
by: Karakiewicz, Pierre I, et al.
Published: (2016)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
by: Gunnarsson, Orvar, et al.
Published: (2015)

Axitinib in Metastatic Renal Cell Carcinoma
by: Mittal, Kriti, et al.
Published: (2012)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
by: Kozloff, M F, et al.
Published: (2012)

Diabetic ketoacidosis after treatment with pembrolizumab
by: M. Hariz. F. Abdul Aziz, et al.
Published: (2017-09-01)

Spotlight on pembrolizumab in the treatment of advanced melanoma
by: Rajakulendran, Thanashan, et al.
Published: (2015)

Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
by: Truong, Phu, et al.
Published: (2016)

Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
by: Alexander, Gregory S., et al.
Published: (2016)

Immune biomarkers of treatment failure for a patient with renal cell carcinoma on a Phase I trial of pembrolizumab plus radiotherapy
by: Alexander, Gregory, et al.
Published: (2015)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
by: Pithavala, Yazdi K., et al.
Published: (2010)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
by: Tortorici, Michael A., et al.
Published: (2010)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
by: Escudier, Bernard, et al.
Published: (2012)

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma
by: Kerr, Lauren T., et al.
Published: (2016)

Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors
by: Hillman, Gilda G., et al.
Published: (2014)

Axitinib: Newly Approved for Renal Cell Carcinoma
by: Tyler, Timothy
Published: (2012)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
by: Dummer, Reinhard, et al.
Published: (2015)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
by: Ueda, Takeshi, et al.
Published: (2013)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
by: Qin, Shukui, et al.
Published: (2015)

Evaluation of dosing strategy for pembrolizumab for oncology indications
by: Tomoko Freshwater, et al.
Published: (2017-05-01)

New developments in the management of advanced melanoma – role of pembrolizumab
by: Improta, Giuseppina, et al.
Published: (2015)

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma
by: Barnhart, Carrie
Published: (2015)

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab
by: Fragkou, Paraskevi, et al.
Published: (2016)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
by: Fujiwara, Yutaka, et al.
Published: (2011)

IBS
Published: (2009)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
by: Ansari, Jawaher, et al.
Published: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni, Elena, et al.
Published: (2014)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
by: Chittoria, Namita, et al.
Published: (2016)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan, Vivek, et al.
Published: (2016)

The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
by: Heine, Annkristin, et al.
Published: (2015)

Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
by: Koie, Takuya, et al.
Published: (2013)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
by: Sugano T, et al.
Published: (2018-09-01)